Abstract: Described is a protective solution for avoiding ischemic, storage or ischemia/reperfusion to organs, or to isolated cell systems, or to tissue components after perfusion, surgery, transplantation, or cryopreservation and subsequent reperfusion, which contains alkali ions, and if need be also alkaline earth ions as the electrolyte, a buffer e.g. on a histidine derivation basis, as well as a polyol and/or a saccharide, has an osmolarity of about 290 mosm/l to about 350 mosm/l, as well as a pH value of about 6.8 to about 7.4, and to which hydroxamic acid, and/or one or more hydroxamic acid derivatives are added.
Type:
Grant
Filed:
May 16, 2003
Date of Patent:
July 12, 2011
Assignee:
Dr. Franz Koehler Chemie GmbH
Inventors:
Herbert de Groot, Ursula Rauen, Gernot Koehler, Wilfried Bruns
Abstract: Disclosed are compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a GluR5 receptor, a GluR6 receptor, or both receptors. The pharmaceutical compositions include and the methods utilize compounds that are analogs and stereoisomers of dysiherbaine and neodysiherbaine which have specificity for kainate receptors.
Type:
Grant
Filed:
October 1, 2008
Date of Patent:
July 5, 2011
Assignee:
Northwestern University
Inventors:
Geoffrey T. Swanson, Leanne Lash, Ryuichi Sakai
Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
July 5, 2011
Assignees:
The United States of America as represented by the Department of Health and Human Services, P2D Inc.
Inventors:
Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg